Amarin Corporationalso Known As Amarin Corp Plcis A Global Pharmaceutical Company Focused On Cardiovascular Healthfounded In 1989 In Englandit Became A Public Company In 1993Amarin Is Dedicated To Developing Innovative Treatments To Manage Cardiovascular Diseaseswith A Vision Of Reducing The Impact Of These Conditions Worldwide The Company S Flagship Productvascepaicosapent Ethyl Was First Approved By The Fda In 2012 For Lowering Triglycerides In Patients With Severe Hypertriglyceridemiavascepa Has Shown Effectiveness In Reducing Cardiovascular Events Through Studies Like The Reduce It Trialamarin Operates A Research And Development Center In Mysticconnecticutwhere It Conducts Clinical Trials To Advance Its Understanding And Treatment Of Cardiovascular Health With A Global Presenceamarin Aims To Positively Impact Cardiovascular Health Through Its Products And Collaborationsthe Company Is Committed To Addressing Cardiovascular Risk And Improving Patient Outcomes Around The World
